New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:07 EDTHZNPDepomed board rejects acquisition proposal from Horizon Pharma
Subscribe for More Information
16:05 EDTHZNPDepomed board rejects takeover proposal from Horizon Pharma
Subscribe for More Information
July 27, 2015
16:45 EDTHZNPLone Pine Capital reports 5.4% passive stake in Horizon Pharma
Subscribe for More Information
07:09 EDTHZNPHorizon Pharma announces collaboration with Fox Chase Cancer Center
Horizon Pharma announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors.
July 24, 2015
11:09 EDTHZNPWallachBeth does not see Horizon facing competing suitor for Depomed
Subscribe for More Information
July 21, 2015
11:28 EDTHZNPDepomed says revised Horizon proposal includes no change to amount of stock
Depomed (DEPO) confirmed that it has received a "purported revised, highly conditional, unsolicited and non-binding" proposal from Horizon Pharma (HZNP) to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share. Depomed said its board, in consultation with its independent financial and legal advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the company and its shareholders. Depomed added: "Today's purported increase does not reflect any increase in the amount of Horizon stock that the Depomed shareholders would receive, nor any increase in the pro-forma ownership for the Depomed shareholders, and is the result of the trading value of Horizon's stock having increased since it made its initial offer." Depomed previously rejected the prior proposal, made May 27, to acquire all outstanding common shares of Depomed in an all-stock transaction then valued at $29.25 per share.
07:02 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
Horizon Pharma (HZNP) announced that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60% premium to the closing price of Depomed on July 6, the day prior to when Horizon's initial proposal was made public.
07:01 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
July 20, 2015
10:33 EDTHZNPDepomed suitor Horizon Pharma advances after raising outlook
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says 'here to stick it out' regarding Depomed deal
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says Depomed proposal 'shareholder friendly'
Subscribe for More Information
09:22 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTHZNPHorizon Pharma up 5.2% after reporting preliminary Q2 revenue, raises FY15 view
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma raises FY15 revenue guidance to $660M-$680M from $590M-$610M
Consensus $611.6M. Raises FY15 adjusted EBITDA guidance to $265M-$280M from $235M-$250M.
07:04 EDTHZNPHorizon Pharma sees Q2 revenue $170M-$172M, consensus $138.26M
July 16, 2015
10:04 EDTHZNPHigh option volume stocks
High option volume stocks: TWX PMCS SHW ASML GRMN GSAT ROVI ALLY LC HZNP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use